[1] Sivaccumar J, Sandomenico A, Vitagliano L, Ruvo M.Monoclonal antibodies: A prospective and retrospective view.
Curr Med Chem. 2020 Feb 19. doi: 10.2174/0929867327666200219142231.
[2] Selis F, Focà G, Sandomenico A, Marra C, Di MauroC, Saccani Jotti G, Scaramuzza S, Politano A, Sanna R, Ruvo M, Tonon G.Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Showa Largely Reduced Affinity for the Target Antigen
Int J Mol Sci. 2016 Apr 1;17(4):491. doi:10.3390/ijms17040491.
[3] Sandomenico A, Sivaccumar JP, Ruvo M. Evolution ofEscherichia coli Expression System in Producing Antibody Recombinant Fragments.Int J Mol Sci. 2020 Aug 31;21(17):6324. doi: 10.3390/ijms21176324.
[4] Focà G, Iaccarino E, Focà A, Sanguigno L,Untiveros G, Cuevas-Nunez M, Strizzi L, Leonardi A, Ruvo M, Sandomenico A.Development of conformational antibodies targeting Cripto-1 with neutralizingeffects in vitro. Biochimie. 2019Mar;158:246-256. doi: 10.1016/j.biochi.2019.01.016. Epub 2019 Jan 28.
[5] Canassa-DeLeo T, Campo VL, Rodrigues LC, MarchioriMF, Fuzo C, Brigido MM, Sandomenico A, Ruvo M, Maranhão AQ, Dias-Baruffi M.Multifaceted antibodies development against synthetic α-dystroglycan mucinglycopeptide as promising tools for dystroglycanopathies diagnostic. GlycoconjJ. 2020 Feb;37(1):77-93. doi: 10.1007/s10719-019-09893-z. Epub 2019 Dec 10.
[6] Calvanese L, Focà A, Sandomenico A, Focà G,Caporale A, Doti N, Iaccarino E, Leonardi A, D'Auria G, Ruvo M, Falcigno L.Structural insights into the interaction of a monoclonal antibody and Nodalpeptides by STD-NMR spectroscopy. Bioorg Med Chem. 2017 Dec15;25(24):6589-6596. doi: 10.1016/j.bmc.2017.10.036. Epub 2017 Oct 28.
[7] Sandomenico A, Focà A, Sanguigno L, Caporale A,Focà G, Pignalosa A, Corvino G, Caragnano A, Beltrami AP, Antoniali G, Tell G,Leonardi A, Ruvo M. Monoclonal antibodies against pools of mono- andpolyacetylated peptides selectively recognize acetylated lysines within thecontext of the original antigen. MAbs. 2016 Nov/Dec;8(8):1575-1589. doi:10.1080/19420862.2016.1225643. Epub 2016 Aug 25.
[8] Sandomenico A, Leonardi A, Berisio R, Sanguigno L,Focà G, Focà A, Ruggiero A, Doti N, Muscariello L, Barone D, Farina C, OwsiankaA, Vitagliano L, Patel AH, Ruvo M. Generation and Characterization ofMonoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope412-422. J Virol. 2016 Jan 27;90(7):3745-59. doi: 10.1128/JVI.02397-15
[9] Strizzi L, Sandomenico A, Margaryan NV, Focà A,Sanguigno L, Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, SeftorRE, Khalkhali-Ellis Z, Leonardi A, Ruvo M, Hendrix MJ. Effects of a novelNodal-targeting monoclonal antibody in melanoma. Oncotarget. 2015 Oct27;6(33):34071-86. doi: 10.18632/oncotarget.6049.
[10] Focà A, Sanguigno L, Focà G, Strizzi L, IannittiR, Palumbo R, Hendrix MJ, Leonardi A, Ruvo M, Sandomenico A. New Anti-NodalMonoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1Binding. Int J Mol Sci. 2015 Sep 7;16(9):21342-62. doi: 10.3390/ijms160921342.
[11] Sandomenico A, Ruvo M. Targeting Nodal andCripto-1: Perspectives Inside Dual Potential Theranostic CancerBiomarkers. Curr Med Chem.2019;26(11):1994-2050. doi: 10.2174/0929867325666180912104707.
[12] Sivaccumar JP, Leonardi A, Iaccarino E, Corvino G, Sanguigno L, Chambery A, Russo R, Valletta M, Latino D, Capasso D, Doti N, Ruvo M, Sandomenico A . Devolopment of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and identification of the Target Epitope by Bio_Layer Interferometry Int J Mol Sci. 2021 Mar 20;22(6):3166. doi: 10.3390/ijms22063166.
[ 14 ] Caporale A, Selis F, Sandomenico A, Jotti GS,Tonon G, Ruvo M. The LQSP tetrapeptide is a new highly efficient substrate ofmicrobial transglutaminase for the site-specific derivatization of peptides andproteins. Biotechnol J. 2015Jan;10(1):154-61. doi: 10.1002/biot.201400466. Epub 2014 Dec 16.
[15] Doti N, Caporale A, Monti A, Sandomenico A, SelisF, Ruvo M. A recent update on the use of microbial transglutaminase for thegeneration of biotherapeutics. World J Microbiol Biotechnol, 2020, 36, (4), 53.
▼ Biomolecules able to modulate the VEGF-dependent angiogenesis |